Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Telix Pharmaceuticals (Innovations) Pty Limited
Quetzal Therapeutics
AbbVie
Rezolute
Hoffmann-La Roche
Genmab
NaviFUS Corporation
Regeneron Pharmaceuticals
BriaCell Therapeutics Corporation
Resilience
Astellas Pharma Inc
Amgen
Eli Lilly and Company
PharmaMar
Amgen
GT Medical Technologies, Inc.
Amgen
AbbVie
University of Vermont
Federation Francophone de Cancerologie Digestive
Daiichi Sankyo
Ruijin Hospital
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
Odense University Hospital
University of California, San Diego
Massachusetts General Hospital
M.D. Anderson Cancer Center
University of Rome Tor Vergata
Federation Francophone de Cancerologie Digestive
Ottawa Hospital Research Institute
Fox Chase Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
Qinghai Red Cross Hospital
University of Aarhus
Sun Yat-sen University
Vastra Gotaland Region
Mabwell (Shanghai) Bioscience Co., Ltd.
Blokhin's Russian Cancer Research Center
Qingdao Central Hospital
Surgimab
Tanta University